Cargando…
Vascular Inflammation and Dysfunction in Lupus-Prone Mice-IL-6 as Mediator of Disease Initiation
Background: Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease and patients are under an increased risk for cardiovascular (CV) events and mortality. The increased CV risk for patients with SLE seems to be caused by a premature and accelerated atherosclerosis, attributab...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956579/ https://www.ncbi.nlm.nih.gov/pubmed/33669022 http://dx.doi.org/10.3390/ijms22052291 |
_version_ | 1783664468465549312 |
---|---|
author | Marczynski, Paul Meineck, Myriam Xia, Ning Li, Huige Kraus, Daniel Roth, Wilfried Möckel, Tamara Boedecker, Simone Schwarting, Andreas Weinmann-Menke, Julia |
author_facet | Marczynski, Paul Meineck, Myriam Xia, Ning Li, Huige Kraus, Daniel Roth, Wilfried Möckel, Tamara Boedecker, Simone Schwarting, Andreas Weinmann-Menke, Julia |
author_sort | Marczynski, Paul |
collection | PubMed |
description | Background: Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease and patients are under an increased risk for cardiovascular (CV) events and mortality. The increased CV risk for patients with SLE seems to be caused by a premature and accelerated atherosclerosis, attributable to lupus-specific risk factors (i.e., increased systemic inflammation, altered immune status), apart from traditional CV risk factors. To date, there is no established experimental model to explore the pathogenesis of this increased CV risk in SLE patients. Methods: Here we investigated whether MRL-Fas(lpr) mice, which develop an SLE-like phenotype, may serve as a model to study lupus-mediated vascular disease. Therefore, MRL-Fas(lpr), MRL-++, and previously generated Il6(−/−) MRL-Fas(lpr) mice were used to evaluate vascular changes and possible mechanisms of vascular dysfunction and damage. Results: Contrary to MRL-++ control mice, lupus-prone MRL-Faslpr mice exhibited a pronounced vascular and perivascular leukocytic infiltration in various organs; expression of pro-inflammatory cytokines in the aorta and kidney was augmented; and intima-media thickness of the aorta was increased. IL-6 deficiency reversed these changes and restored aortic relaxation. Conclusion: Our findings demonstrate that the MRL-Fas(lpr) mouse model is an excellent tool to investigate vascular damage in SLE mice. Moreover, IL-6 promotes vascular inflammation and damage and could potentially be a therapeutic target for the treatment of accelerated arteriosclerosis in SLE. |
format | Online Article Text |
id | pubmed-7956579 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79565792021-03-16 Vascular Inflammation and Dysfunction in Lupus-Prone Mice-IL-6 as Mediator of Disease Initiation Marczynski, Paul Meineck, Myriam Xia, Ning Li, Huige Kraus, Daniel Roth, Wilfried Möckel, Tamara Boedecker, Simone Schwarting, Andreas Weinmann-Menke, Julia Int J Mol Sci Article Background: Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease and patients are under an increased risk for cardiovascular (CV) events and mortality. The increased CV risk for patients with SLE seems to be caused by a premature and accelerated atherosclerosis, attributable to lupus-specific risk factors (i.e., increased systemic inflammation, altered immune status), apart from traditional CV risk factors. To date, there is no established experimental model to explore the pathogenesis of this increased CV risk in SLE patients. Methods: Here we investigated whether MRL-Fas(lpr) mice, which develop an SLE-like phenotype, may serve as a model to study lupus-mediated vascular disease. Therefore, MRL-Fas(lpr), MRL-++, and previously generated Il6(−/−) MRL-Fas(lpr) mice were used to evaluate vascular changes and possible mechanisms of vascular dysfunction and damage. Results: Contrary to MRL-++ control mice, lupus-prone MRL-Faslpr mice exhibited a pronounced vascular and perivascular leukocytic infiltration in various organs; expression of pro-inflammatory cytokines in the aorta and kidney was augmented; and intima-media thickness of the aorta was increased. IL-6 deficiency reversed these changes and restored aortic relaxation. Conclusion: Our findings demonstrate that the MRL-Fas(lpr) mouse model is an excellent tool to investigate vascular damage in SLE mice. Moreover, IL-6 promotes vascular inflammation and damage and could potentially be a therapeutic target for the treatment of accelerated arteriosclerosis in SLE. MDPI 2021-02-25 /pmc/articles/PMC7956579/ /pubmed/33669022 http://dx.doi.org/10.3390/ijms22052291 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Marczynski, Paul Meineck, Myriam Xia, Ning Li, Huige Kraus, Daniel Roth, Wilfried Möckel, Tamara Boedecker, Simone Schwarting, Andreas Weinmann-Menke, Julia Vascular Inflammation and Dysfunction in Lupus-Prone Mice-IL-6 as Mediator of Disease Initiation |
title | Vascular Inflammation and Dysfunction in Lupus-Prone Mice-IL-6 as Mediator of Disease Initiation |
title_full | Vascular Inflammation and Dysfunction in Lupus-Prone Mice-IL-6 as Mediator of Disease Initiation |
title_fullStr | Vascular Inflammation and Dysfunction in Lupus-Prone Mice-IL-6 as Mediator of Disease Initiation |
title_full_unstemmed | Vascular Inflammation and Dysfunction in Lupus-Prone Mice-IL-6 as Mediator of Disease Initiation |
title_short | Vascular Inflammation and Dysfunction in Lupus-Prone Mice-IL-6 as Mediator of Disease Initiation |
title_sort | vascular inflammation and dysfunction in lupus-prone mice-il-6 as mediator of disease initiation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956579/ https://www.ncbi.nlm.nih.gov/pubmed/33669022 http://dx.doi.org/10.3390/ijms22052291 |
work_keys_str_mv | AT marczynskipaul vascularinflammationanddysfunctioninlupuspronemiceil6asmediatorofdiseaseinitiation AT meineckmyriam vascularinflammationanddysfunctioninlupuspronemiceil6asmediatorofdiseaseinitiation AT xianing vascularinflammationanddysfunctioninlupuspronemiceil6asmediatorofdiseaseinitiation AT lihuige vascularinflammationanddysfunctioninlupuspronemiceil6asmediatorofdiseaseinitiation AT krausdaniel vascularinflammationanddysfunctioninlupuspronemiceil6asmediatorofdiseaseinitiation AT rothwilfried vascularinflammationanddysfunctioninlupuspronemiceil6asmediatorofdiseaseinitiation AT mockeltamara vascularinflammationanddysfunctioninlupuspronemiceil6asmediatorofdiseaseinitiation AT boedeckersimone vascularinflammationanddysfunctioninlupuspronemiceil6asmediatorofdiseaseinitiation AT schwartingandreas vascularinflammationanddysfunctioninlupuspronemiceil6asmediatorofdiseaseinitiation AT weinmannmenkejulia vascularinflammationanddysfunctioninlupuspronemiceil6asmediatorofdiseaseinitiation |